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Extensive cellular heterogeneity exists within spe-
cific immune-cell subtypes classified as a single
lineage, but its molecular underpinnings are rarely
characterized at a genomic scale. Here, we use
single-cell RNA-seq to investigate the molecular
mechanisms governing heterogeneity and pathoge-
nicity of Th17 cells isolated from the central nervous
system (CNS) and lymph nodes (LN) at the peak
of autoimmune encephalomyelitis (EAE) or diff-
erentiated in vitro under either pathogenic or non-
pathogenic polarization conditions. Computational
analysis relates a spectrum of cellular states in vivo
to in-vitro-differentiated Th17 cells and unveils
genes governing pathogenicity and disease suscep-
tibility. Using knockout mice, we validate four new
genes: Gpr65, Plzp, Toso, and Cd5l (in a companion
paper). Cellular heterogeneity thus informs Th17
function in autoimmunity and can identify targets
for selective suppression of pathogenic Th17 cells
while potentially sparing non-pathogenic tissue-
protective ones.1400 Cell 163, 1400–1412, December 3, 2015 ª2015 Elsevier Inc.INTRODUCTION
The immune system strikes a balance between mounting
proper responses to pathogens and avoiding autoim-
mune reactions. In particular, as part of the adaptive im-
mune system, pro-inflammatory IL-17-producing Th17 cells
mediate clearance of fungal infections and other pathogens
(Herna´ndez-Santos and Gaffen, 2012) and maintain mucosal
barrier functions (Blaschitz and Raffatellu, 2010) but are also
implicated in pathogenesis of autoimmunity (Korn et al.,
2009).
Mirroring this functional diversity, in vitro polarized Th17
cells can either cause severe autoimmune responses upon
adoptive transfer (‘‘pathogenic,’’ polarized with IL-1b+IL-6+IL-
23) or have little or no effect in inducing autoimmune disease
(‘‘non-pathogenic,’’ polarized with TGF-b1+IL-6) (Ghoreschi
et al., 2010; Lee et al., 2012).
Analysis of these states has been limited, however,
by relying either on genomic profiling of cell populations,
which cannot distinguish distinct states within them, or on
tracking a few known markers by flow cytometry (Perfetto
et al., 2004). Single-cell RNA-seq (Shalek et al., 2013,
2014; Trapnell et al., 2014) opens the way for a more unbi-
ased interrogation of cell states, including in limited in vivo
samples.
Here, we use single-cell RNA-seq to show that cells isolated
from the draining LNs andCNS at the peak of EAE exhibit diverse
functional states, and we relate them to a spectrum spanning
from more regulatory to more pathogenic cells observed in
Th17 cells polarized in vitro. Genes associated with these
opposing states include both canonical known regulators and
novel candidates. We validated four high-ranking candidates—
Gpr65, Plzp, Toso, and Cd5l (the latter in a companion study in
this issue of Cell [Wang et al., 2015])—with knockout mice, un-
covering substantial effects on in vitro differentiation and in vivo
EAE development.
RESULTS
RNA-Seq Profiling of Single Th17 Cells Isolated In Vivo
and In Vitro
We profiled the transcriptome of 976 Th17 cells (ultimately
retaining 722 cells, below), either harvested in vivo or differenti-
ated in vitro (Figure 1A, Table S1, and Experimental Procedures).
In vivo, we induced EAE by myelin oligodendrocyte glycoprotein
(MOG35-55) immunization, harvested CD3
+CD4+IL-17A/GFP+
cells from the draining LNs and CNS at the peak of disease,
and profiled them promptly. In vitro, we profiled CD4+ naive
T cells at 48 hr of activation under TGF-b1+IL-6 or IL-1b+
IL-6+IL-23. We prepared mRNA SMART-seq libraries using mi-
crofluidic chips (Fluidigm C1), followed by transposon-based
library construction.
We removed 254 cells (26%) by quality metrics (Supple-
mental Experimental Procedures), and we controlled for quanti-
tative confounders and batch effects (Experimental Procedures
and Figures S1A and S1B). We retained 7,000 appreciably ex-
pressed genes (fragments per kilobase of exon per million
[FPKM] > 10 in at least 20% of cells in each sample) for in vitro
experiments and 4,000 for in vivo ones. To account for ex-
pressed transcripts that are not detected (false negatives) due
to the limitations of single-cell RNA-seq (Deng et al., 2014; Sha-
lek et al., 2014), we down-weighted the contribution of less
reliably measured transcripts (Figure S1C and Experimental Pro-
cedures). Following these filters, expression profiles tightly
correlated between population replicates (Figure 1B) and be-
tween the average expression across single cells and thematch-
ing population profile (r  0.65–0.93; Figures 1C, S1D, and S2).
However, we found substantial differences in expression be-
tween individual cells in the same condition (r 0.45–0.75, Fig-
ures 1D, 1E, and S1D), comparable to previous observations in
other immune cells (Shalek et al., 2014). We validated the
observed expression patterns for eight representative genes
with flow RNA-fluorescence in situ hybridization (Supplemental
Experimental Procedures) (Figures 1F, 1G, and S1E). While
most transcripts (e.g., Irf4, Batf, Actb) are expressed unimodally
or nearly so (e.g., Rorc), some key transcripts (e.g., Il17a) exhibit
a bimodal distribution, suggesting functional variation.
A Functional Annotation of Single-Cell Heterogeneity
Shows that Th17Cells Span a Spectrum of States In Vivo
To study the main sources of cellular variation in vivo, we used a
principal component analysis (PCA, Figure 2A) followed by a
novel analysis for functional annotation of the principal compo-nent (PC) space based on the single-cell expression of gene
signatures of known T cell states (Figure 2B and Experimental
Procedures), such that each signature is scored for its associa-
tion with each PC. To identify transcription factors that may
orchestrate this heterogeneity, we identified factors whose tar-
gets are strongly enriched (Fisher’s exact test, p < 105) in genes
that correlated with each PC (Pearson correlation, FDR < 0.05;
Figures 2E and 2F and Table S3).
The first PC (PC1) positively correlates with a recently defined
effector versus memory signature following viral infection (Craw-
ford et al., 2014) and negatively correlateswith a signature charac-
terizing memory T cells (Wherry et al., 2007) (Figure 2A and Table
S2). This suggests that cells span from effector (high positive PC1
scores) to memory (high negative PC1 scores) phenotypes. PC2
separates cells by their source of origin (CNSor LN) and correlates
with a transition from a naive-like state (negatively correlated with
PC2; p < 1042, Figure 2A and Table S2) with low cell-cycle activity
(FDR < 5%) to a Th1-like effector or memory effector state (posi-
tively correlated with PC2, Figure 2A, p < 1021 and p < 1057,
respectively).
A Trajectory of Progressing Cell States from the LN to
the CNS
To further explore the diversity of LN and CNS cells, we used five
of the key signatures discovered by our functional annotation to
define Voronoi regions that divide the PCA space into subpopu-
lations of cells (Supplemental Experimental Procedures, Fig-
ure 2C, and Table S2). We identified genes characterizing each
group by differential expression (KS test, FDR < 0.05; Table
S4). For brevity, we assign new labels to these subpopulations
(Th17 self-renewing, Th17/Th1-like effector, etc.), based on
strong correlation with previous signatures and known genes
(below); any such label may inevitably fall short of capturing
the complex underlying biology.
Overall, the cells gradually progress through from a self-re-
newing-like state in the LN to a pre-Th1 effector-like phenotype
in the LN and CNS to a Th1-like effector state and a Th1-like
memory state in the CNS and, finally, a less functional state in
the CNS. First, self-renewing-like Th17 cells in the LN (Figure 2C)
are characterized by: (1) a signature of Wnt signaling (p < 104,
KS test comparing the signature score to all other subpopula-
tions; Figure 2A) (Reya et al., 2003) and high expression of Tcf7
(Figure 2D), a key Wnt target and transcription factor regulating
the stem cell-like state of Th17 cells (Muranski et al., 2011); (2)
high expression ofCd62l (Figure 2D), a known naive statemarker
(De Rosa et al., 2001); and (3) upregulation (Figure 2D) ofCd27, a
pro-survival gene lacking in short-lived T cells (Dolfi et al., 2008;
Hendriks et al., 2000). Our analysis (Figure 2E) suggests that
Etv6, Med12, and Zfx drive this self-renewing population (Dis-
cussion). Next, cells from the LN andCNS adopt similar (overlap-
ping) cell states in the central region of our PCA plot (Figure 2C),
reflecting effector Th17-like cells with a pre-Th1-like phenotype,
characterized by induction of receptors for IFN (Ifngr2) and IL-18
(Il18r1, Figure 2D) (Holzer et al., 2013), and of chemokine recep-
tors Cxcr6 (Figure 2D) (Aust et al., 2005) and Ccr2 (Figure 2D)
(Mahad and Ransohoff, 2003), which may all poise the cells for
recruitment to the CNS. In turn, IL-17A/GFP+-sorted cells ac-






Figure 1. Single-Cell RNA-Seq of Th17 Cells In Vivo and In Vitro
(A) Experimental setup.
(B–E) Quality of single-cell RNA-seq. Scatter plots (B–D) compare transcript expression (FPKM+1, log10) from the in vitro TGF-b1+IL-6 48 hr condition between
two bulk population replicates (B), the ‘‘average’’ of single-cell profile and a matched bulk population control (C), or two single cells (D). Histograms (E) depict the
distributions of Pearson correlation coefficients (x axis) between single cells and their matched population control and between pairs of single cells.
(F andG) Comparison to RNA Flow-FISH. (F) Expression distributions by RNA-seq and RNA Flow-FISH at 48 hr under the TGF-b1+IL-6 in vitro condition. Negative
control: bacterial DapB gene.
(G) Bright-field and fluorescence channel images of RNA Flow-FISH in negative (left) and positive (right) cells.
See also Figure S1 and Table S1.with upregulation (p < 103, KS test, Table S4) of: Ifn-g (Fig-
ure 2D), Rankl, (Tnfsf11) (Nakae et al., 2007; Komatsu et al.,
2014), and cell-cycle genes (e.g., Geminin, Figure 2D), a strong
correlation with a salt-induced pathogenic Th17 cell signature
(Wu et al., 2013) (Figure 2A), and association with both canonical1402 Cell 163, 1400–1412, December 3, 2015 ª2015 Elsevier Inc.Th17 TFs (Stat3 andHif1a) and Th1-associated factors, including
Rel and Stat4 (Figure 2E), which are associated with EAE (Hilliard
et al., 2002; Mo et al., 2008) or with human autoimmune disease
(Gilmore and Gerondakis, 2011). These cells could either be sta-
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Th1 lineage (Discussion). Next, Th1-like memory cells detected
in the CNS (Figure 2C) correlate highly with both a memory
phenotype (negative PC1) and a Th1-like phenotype (positive
PC2), upregulating (p < 103, KS test, Table S4) memory signa-
ture genes (e.g., Nur77, Samsn1, Il2ra, Il2rb, Tigit, Ifngr1, and
Il1r2) and pro-inflammatory genes (Csf2 and Gpr65; Figure 2D)
and associated with Hif1a regulation (Figure 2F), crucial for con-
trolling human Th17 cells to become long-lived effector memory
cells (Kryczek et al., 2011). Finally, a few Th17 cells may even ac-
quire a somewhat senescent-like phenotype in the CNS (nega-
tive PC1 and PC2 scores; Figure 2C), correlating with a signature
comparing CD4 T cells at day 30 during a chronic infection to
those during acute infection (Table S2) and downregulation
(p102, KS test, Table S4) of some T cell activation genes (Fig-
ure 2D and Table S4).
Further supporting the interpretation of gradual progression,
most in vivo cells are maximally correlated with bulk profiles at
48–72 hr during Th17 cell differentiation in vitro (Yosef et al.,
2013) (Figure S4B), but some cells, especially from the LN, corre-
late most strongly with earlier time points. Indeed, time point an-
notations positively correlate with PC2 (r0.5; p < 1027, Figures
2A and S4D). Finally, a population-based signature comparing
profiles of EAE Th17 cells to lamina propria lymphocyte (LPL)
Th17 cells (Supplemental Experimental Procedures and Fig-
ure S3), which are known to assume a regulatory phenotype (Es-
plugues et al., 2011; O’Connor et al., 2009), correlates with PC1
in vivo (p < 1025, Figure 2A, Table S2), indicating that EAE-
derived Th17 cells adopt a stronger effector phenotype than
gut-derived Th17 cells.In-Vitro-Derived Cells Span a Spectrumof Pathogenicity
States with Similarities and Distinctions from In Vivo
Isolated Cells
Given the limited cell availability from in vivo samples and the fact
that cells are obtained as a mixed ‘‘snapshot’’ of an asynchro-
nous process, it is difficult to further characterize their distinct
pathogenic potential. A complementary strategy is to profile
Th17 cells differentiated in vitro and compare in vivo and
in vitro profiles.
We analyzed single-cell RNA-seq profiles of 420 Th17 cells
derived under non-pathogenic (TGF-b1+IL-6, unsorted: 130
cells from 2 biological replicates and TGF-b1+IL-6; sorted for
IL-17A/GFP+: 151 cells from 3 biological replicates) and patho-Figure 2. Th17 Cells Span a Progressive Trajectory of States from the
(A) PCA separates CNS-derived cells from LN-derived cells. Shown are 302 cells i
correlate with PC1 or PC2 (p < 106, Table S2, Supplemental Experimental Proc
(B) Functional annotation. Top to bottom: Gene signatures are defined from lite
correlation coefficient is calculated between the signature score and the PC load
(Supplemental Experimental Procedures).
(C) Five progressive Th17 cell states from the LN to the CNS. Plot as in (A), but wit
the cells populating the extremities of PCA space; five signature-specific subpo
replicates of one of the two in vivo biological replicates, potentially due to differe
(D) Example genes that distinguish each subpopulation. Cumulative distribution
corresponds to CNS/LN cells, respectively, where appropriate.
(E and F) Transcription factors (nodes) whose targets are significantly enriched in
and are colored according to the loading of the encoding gene in the respective
See also Figures S2, S3, and S4 and Tables S2, S3, and S4.
1404 Cell 163, 1400–1412, December 3, 2015 ª2015 Elsevier Inc.genic conditions (Il-1b+IL-6+IL-23, sorted for IL-17A/GFP+: 139
cells from 2 biological replicates) (Figure 3A).
Using our functional annotation approach (Figure 2B), we find
that in-vitro-differentiated Th17 cells vary strongly in a key path-
ogenicity signature (Lee et al., 2012), reflecting their respective
conditions (Figures 3A and 3D). High pathogenicity scores
were associated with IL-17A/GFP+-sorted cells polarized under
the pathogenic condition (Figures 3A and 3D), whereas IL-17A/
GFP+-sorted cells from non-pathogenic conditions correlate
highly with expression of regulatory cytokines (e.g., IL-10) and
their targets, which are barely detected in pathogenic cells (Fig-
ure 3E). There is a zone of overlap in cell states between the path-
ogenic and non-pathogenic conditions (Figure 3A), with cells
polarized under the non-pathogenic (TGF-b1+IL-6) condition
that were not sorted to be IL-17A/GFP+ spanning the broadest
pathogenicity spectrum (Figures 3A and 3D). A signature from
IL-23R/cells differentiated with IL-1b+IL-6+IL-23 (Y.L. and
V.K.K, unpublished data) correlates highly with the more regula-
tory cells, confirming the role of the IL-23 pathway in pathoge-
nicity (Figure 3A).
As expected, the most cells’ profiles correlate with bulk pro-
files at 48–50 hr (Yosef et al., 2013) (Figure S4A). The correlated
time points match with variation along PC2 (Figure 3A), but not
PC1, suggesting that pathogenicity is not a reflection of the cell’s
position along the differentiation trajectory but is an orthogonal
aspect of cell state.
To relate the in-vitro-differentiated cells to their in vivo
counterparts, we scored the in vitro cells for signatures of
immune-related genes that characterize the in-vivo-identified
subpopulations (Figures 2C, 3B, and 3C and Supplemental
Experimental Procedures). Cells derived in the non-patho-
genic conditions score higher for the Th17 self-renewing-
like signature (p < 1010, KS test; Table S2 and Figures 3A
and 3C), whereas those derived in pathogenic conditions
resemble the Th17/Th-1 like memory phenotype identified
in the CNS (p < 103, KS test; Figures 3A and 3B and Table
S2).
Co-variation with Pro-inflammatory and Regulatory
Modules in Th17 Cells Highlights Novel Candidate
Regulators
We analyzed each gene’s variation in expression across the
unsorted cells from the TGF-b1+IL-6 differentiation condition.
About 35% (2,252) of the detected genes are expressedLN to the CNS
n the space of the first two PCs. Numbered circles: signatures that significantly
edures).
rature, and a signature score is calculated for each single cell. The Pearson
ing for each cell and PC and is plotted on the PCA plot (circled numbers in A)
h Voronoi cells, defined by signatures (colored circles, Table S2) characterizing
pulations are marked. The self-renewing state was observed in two technical
nces in disease induction or progression.
function (CDF) plots of expression for key selected genes. Dotted/solid line
PC2 (E) or PC1 (F). Nodes are sized proportionally to fold enrichment (Table S3)
PC (loadings were normalized to have zero mean and SD of 1).
AB C D E
Figure 3. A Spectrum of Pathogenicity States In Vitro
(A) PCA plot of Th17 cells differentiated in vitro. PC1 separates cells from most (left) to least (right) pathogenic, as indicated by both the differentiation condition
(color code) and the correlated signatures (numbered circles).
(B–D) Key signatures related to pathogenicity. CDFs of the single-cell scores for key signatures for the three in vitro populations (colored as in A): (B) a signature
distinguishing the in vivo Th17/Th1-like memory subpopulation (blue in Figure 2C); (C) a signature distinguishing the in vivo Th17 self-renewing subpopulation
(green in Figure 2C); and (D) a signature of pathogenic Th17 cells (Lee et al., 2012).
(E) CDFs of expression level (FPKM+1, log10) of Il10 for the three in vitro populations.
See also Table S2.in >90% of the cells (Figure 4A) with a unimodal distribution:
these include housekeeping genes (p < 1010, hypergeometric
test, Figures S5A and S5B), the Th17 signature cytokine Il17f,
and transcription factors that are essential for Th17 differentia-
tion (e.g., Batf, Stat3, Rorc, and Hif1a). Bimodally expressed
genes—with high expression in at least 20% of the cells and
much lower (often undetectable) levels in the rest—include
inflammatory and regulatory cytokines and their receptors
(e.g., Il17a, Il10, Il21, Ccl20, Il24, and Il27ra; Figure 4A). Expres-
sion variationmay bemore strongly related to pathogenicity than
differentiation. Most (>75%) cells express pioneer and master
transcription factors for the Th17 lineage (Rorc, Irf4, and Batf),
but some also express transcripts encoding key genes from
other T cell lineages (e.g., Stat4 for Th1 cells, Ccr4 for Th2 cells),
suggesting the presence of previously reported ‘‘hybrid’’ double-
positive cells (Antebi et al., 2013) and/or reflecting our model of
duality in the Th17 transcriptional network (Yosef et al., 2013).
The expression of many key immune genes varies more than
that of other transcripts with the same mean expression level
(Figure S5C), even when only considering the expressing cells
(Figure S5D), implying a greater degree of diversity in immune-gene regulation. Such patterns must be interpreted with caution
because some (e.g., Il17a, Il24, and Ccl20), but not all (e.g., Il9),
of the transcripts with bi-modal patterns are lowly expressed and
thus may be less reliably detected and also because transcrip-
tion bursts coupled with transcript instability may lead to
‘‘random’’ fluctuations.
To overcome these challenges, we analyzed co-variation be-
tween transcripts across cells (Figure 4B), reasoning that, if vari-
ation reflects distinct cell states, entire gene modules should
robustly co-vary across cells. Focusing on significant co-varia-
tion (Spearman correlation; FDR < 0.05) between bimodally
expressed transcripts (expressed by less than 90% of cells; Fig-
ure 4B, rows, Supplemental Experimental Procedures) and a
curated set of bimodally expressed immune response genes
(Figure 4B, columns), we find two key transcript modules: one
that co-varies with known pro-inflammatory Th17 cytokines,
such as Il17a and Ccl20, and another that co-varies with known
regulatory genes such as Il10, Il24, and Il9.
Using these modules as signatures to annotate the original
in vitro cell states (Figure 4C), we find that a signature comparing
the module co-varying with pro-inflammatory genes to theCell 163, 1400–1412, December 3, 2015 ª2015 Elsevier Inc. 1405
module co-varying with regulatory genes strongly correlates with
the most pathogenic cells (Figures 4C and 4D). We find further
support from additional signatures and analyses: (1) a negative
correlation between PC1 scores and a curated pathogenicity
signature (Lee et al., 2012) and a positive correlation between
PC1 and Tr1exTh17 cells versus Th17 cell signature (Gagliani
et al., 2015) (Figure 4C and Table S2); (2) correlation with the in-
flammatory CNS-derived Th17 cells in vivo (Figure 2A); (3)
enrichment of genes in the co-variation modules (rows of Fig-
ure 4B) for immune response genes (using MSigDB [Liberzon
et al., 2011]; Table S5) for genes generically associated with in-
flammatory bowel disease (Jostins et al., 2012) and rheumatoid
arthritis (Okada et al., 2014) (p < 106; hypergeometric test) and
for genes upregulated in cortical lesions derived from patients
with progressive multiple sclerosis (Fischer et al., 2013) (p <
0.02, hypergeometric test).
These co-variation modules highlight novel putative regula-
tors, many not detected or prioritized by previous population-
level approaches (Ciofani et al., 2012; Yosef et al., 2013). We
prioritized follow-up candidates with a computational ranking
scheme (Experimental Procedures). While the genes from our
co-variation matrix (rows, Figure 4B) tend to be highly ranked
compared to all genes also in bulk-population data (p < 1010,
Wilcoxon rank-sum test) or rankings (Ciofani et al., 2012) (Table
S7 and Supplemental Experimental Procedures), they do not
necessarily stand out in bulk population rankings (Figure S6),
highlighting the distinct signal from single-cell profiles. Based
on our ranking and knockout mice availability, we chose four
genes novel to Th17 function for functional follow up: Gpr65,
Toso, Plzp, and Cd5l (the latter presented in Wang et al., 2015).
Gpr65 Promotes Th17 Cell Pathogenicity and Is
Essential for EAE
Gpr65, a glycosphingolipid receptor, is a member of the module
co-varying with pro-inflammatory genes (Figure 4B) and is highly
expressed in our Th1-like effector/memory cells (Figure 2D). Ge-
netic variants in the Gpr65 locus are associated with multiple
sclerosis (Sawcer et al., 2011), ankylosing spondylitis (Cortes
et al., 2013), inflammatory bowel disease (Jostins et al., 2012),
and Crohn’s disease (Franke et al., 2010).
Naive Gpr65/ T cells differentiated with TGF-b1+IL-6 or
IL-1b+IL-6+IL-23 for 96 hr show a 40% reduction of IL-17A+
cells compared toWT controls (Figure 5A), asmeasured by intra-
cellular cytokine staining (ICC, Supplemental Experimental
Procedures). Memory cells from Gpr65/ mice also showed
an 45% reduction in IL-17A+ cells after reactivation with
IL-23 (Figure S7A). There was a reduced secretion of IL-17A
(p < 0.01) and IL-17F (p < 104) under pathogenic differentiation
conditions in the knockout cells (Figure 5B) and increased IL-10
secretion (p < 0.01, Figure S7C) (Supplemental Experimental
Procedures).
RNA-seq profiles (Supplemental Experimental Procedures) of
populations of Gpr65/ Th17 cells, differentiated under both
non-pathogenic and pathogenic conditions for 96 hr, show that
genes upregulated in Gpr65/ cells are most strongly enriched
(p < 1028, hypergeometric test, Figure 5E) for the genes charac-
terizing the more regulatory Th17 cells (positive PC1, Figure 4C,
Table S6, and Supplemental Experimental Procedures). More-1406 Cell 163, 1400–1412, December 3, 2015 ª2015 Elsevier Inc.over, ChIP-seq analysis (Ciofani et al., 2012) indicates thatRorgt,
the Th17 cell master transcription factor, binds the promoter re-
gion of Gpr65.
To determine the effect of loss of GPR65 on autoimmune
disease, we reconstituted RAG-1/ mice with naive WT or
Gpr65/ CD4+ T cells and induced EAE (Supplemental Experi-
mental Procedures). In the absence ofGpr65-expressing T cells,
mice are protected from EAE (Figures 5D and S7D), and far fewer
IL-17A and IFN-g positive cells are recovered from the LN and
spleen compared to WT controls (Figure S7B). Furthermore,
in vitro restimulation with MOG35-55 of the spleen and LN cells
from immunizedmice showed that loss of GPR65 resulted in dra-
matic reduction of MOG35-55-specific IL-17A or IFN-g-positive
cells (Figure 5C), suggesting that GPR65 regulates encephalito-
genic T cells generation in vivo.
Toso Is Implicated in Th17 Pathogenicity
Toso (Faim3) is an immune-cell-specific surface molecule that
negatively regulates Fas-mediated apoptosis (Hitoshi et al.,
1998) and a member of the module co-varying with regulatory
genes (Figure 4B). While this may naively suggest that TOSO
would enhance regulatory mechanisms, Toso/mice are resis-
tant to EAE (Lang et al., 2013). Toso could therefore be a negative
regulator of the non-pathogenic state.
Supporting this hypothesis, Toso/ cells showed a defect in
the production of the pro-inflammatory cytokine IL-17A for
both differentiation conditions (Figures 5F and 5G), and memory
Toso/ cells stimulated with IL-23 lacked IL-17A production
(Figure S7E). In a MOG35-55 recall assay, CD3
+CD4+ Toso/
T cells showed no IL-17A production (Figure 5H). This supports
a role for Toso as a promoter of pathogenicity.
Population RNA-seq analysis shows that loss of TOSO results
in suppression of the key regulatory genes (e.g., Il24, Il9, and
Procr; Table S6), consistent with an IL-10 reduction measured
by ELISA (Figure S7G) and a reduced FOXP3+ cell count during
Treg differentiation (TGF-b1, Figure S7F). On the other hand, in
the pathogenic condition, Il17a is downregulated in the absence
of TOSO. Enrichment analysis with respect to PC1 of the non-
pathogenic condition suggests that Toso/ cells, rather than
upregulating regulatory genes, downregulate genes associated
with a more pro-inflammatory phenotype (Figure 5E). Toso is
also bound byRorgt (Ciofani et al., 2012), providing an additional
Th17-specific mechanism of action.
MOG35-55-Stimulated Plzp
/ Cells Have a Defect in
Generating Pathogenic Th17 Cells
The transcription factor Plzp (Rog, Zbtb32) is a known repressor
of the Th2 master regulator Gata3 and regulates cytokine
expression (Miaw et al., 2000) in T-helper cells. We hypothesized
that Plzp regulates pathogenicity in Th17 cells, but we could not
undertake an EAE experiment since Plzp/mice were not avail-
able on an EAE-susceptible background.
While in-vitro-differentiated Plzp/ cells produced similar IL-
17A levels as WT controls (Figure S7H), a MOG35-55 recall assay
revealed a defect in IL-17A production, with increasingMOG35-55
concentration during restimulation (Figure 5I). When reactivated
in the presence of IL-23, which expands in-vivo-generated Th17
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appears to influence the expression of a wider range of in-
flammatory cytokines, as Plzp/ T cells secreted less IL-17A,
IL-17F (Figure 5J), IFN-g, IL-13, and CSF2 (Figure S7J).
Based on RNA-seq profiles at 48 hr of non-pathogenic differ-
entiation of Plzp/ cells, Irf1, Il9, and other transcripts of the
module co-varying with regulatory genes are upregulated (Table
S6), whereas transcripts from themodule co-varying with pro-in-
flammatory genes (e.g., Ccl20, Tnf, Il17a) are repressed, and
genes characterizing the more pro-inflammatory cells (PC1, Fig-
ure 4C) are strongly enriched among the downregulated genes
(Figure 5E).
DISCUSSION
Here, we show how variation and co-variation in single-cell pro-
files can be leveraged to identify key regulatory modules and the
factors that may control them to dissect Th17 cell pathogenicity
beyond differentiation.
In vivo, we used variation to infer the life cycle of Th17 cells.
Processes such as self-renewal, observed in the LN, may pro-
vide a pool of cells that are precursors for differentiating Th17
cells to effector/ memory formation in the CNS. The Th1-like
phenotype that we observe in the CNS may be the most patho-
genic (Bending et al., 2009; Lee et al., 2009; Muranski et al.,
2011) and might facilitate memory cell formation, as the entry
of Th1 cells into the memory pool is well established (Sallusto
et al., 1999). It is unclear whether cells that adopt a Th1 pheno-
type are stable ‘‘double producers’’ or whether they show plas-
ticity toward a Th1 fate.
We used transcription factor target enrichment analysis in vivo
to nominate key regulators of each state. For example,wepredict
thatMed12, Etv6, and Zfx drive the Th17 self-renewing-like sub-
population in the LN. While neither has been linked to Th17 self-
renewal, each has been associated with self-renewal and related
functions in other cells (Rocha et al., 2010; Hock et al., 2004; Tsu-
zuki and Seto, 2013; Galan-Caridad et al., 2007). For the patho-
genic effector and memory cells observed in the CNS during
EAE,weassign aprominent role to knownTh17/Th1 transcription
factors such as Hif1a, Fosl2, Stat4, and Rel.
In vitro, we used strong co-variation, most pronounced under
the least pathogenic and most variable conditions to rank candi-
date genes, such as Cd5l and Gpr65, based on their association
with known regulatory and pro-inflammatory genes. Con-
sistently, a lack of both Cd5l and Gpr65 significantly alters EAE
disease progression. Genes similarly associated with pro-in-Figure 4. Modules of Genes that Co-vary with Pro-inflammatory and R
(A) Single-cell expression distribution of genes. The heatmap shows for each ge
TGF-b1+IL-6 condition for 48 hr (without further IL-17A-based sorting). Color sca
Genes are sorted from more unimodal (top) to bimodal (bottom).
(B) Modules co-varying with pro-inflammatory and regulatory genes. Heatmap of t
of signature genes of pathogenic T cells (Lee et al., 2012) or of other CD4+ lineag
gene (rows) in cells differentiated under the TGF-b1+IL-6 condition at 48 hr. Gen
(C) The modules co-varying with pro-inflammatory and regulatory genes distingui
comparing the two co-variation modules.
(D) Expression of key module genes. Each panel shows the PCA plot of (C) where
(E) A ranking of the top 100 candidate genes co-varying with pro-inflammatory or
ranking scores (bar chart, Supplemental Experimental Procedures).
See also Figures S5 and S6 and Tables S2 and S5 related to Figure 4.
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include: Gem, Tmem109, and cd226. Conversely, Foxp1, a
member of the module co-varying with regulatory genes, was
highly expressed in the LN-derived Th17 self-renewing subpop-
ulation and the gut-derived Th17 cells (Figure S3). Foxp1 nega-
tively regulates IL-21, a driver of Th17 generation (Korn et al.,
2007), and dampens T cell activation (Wang et al., 2014). Co-
variation of a gene with a particular module does not, however,
necessarily indicate similar function of this gene with other genes
in the module, as we have seen for Toso. Another example, Lag-
3, is upregulated during T-cell activation but suppresses it
(Grosso et al., 2007). This is consistent with amodel in which reg-
ulators with opposite, antagonistic functions are co-regulated.
Whereas population-based expression profiling has identified
genes that govern the differentiation states of Th17 cells, single-
cell RNA-seq provides new granularity to unveil potent candi-
dates for manipulation of pathogenicity of Th17 cells without
affecting nonpathogenic Th17 cells that may be critical for tissue
homeostasis and for maintaining barrier functions.
EXPERIMENTAL PROCEDURES
Additional analyses and details are in the Supplemental Experimental
Procedures.
Mice, EAE Induction, and Cell Isolation
C57BL/6WT andCD4/ (2663)micewere obtained from Jackson Laboratory.
IL-17A–GFP+ mice were obtained from Biocytogen. Gpr65/, Plzp/, and
Toso/ mice were provided by Li Yang, Pier Paolo Pandolfi, and John Coli-
gan, respectively. All animals, unless noted otherwise, were housed and main-
tained in a conventional pathogen-free facility at the Harvard Institute of
Medicine in Boston (Supplemental Experimental Procedures). EAE induction
and disease analysis, isolation of T cells from EAEmice at the peak of disease,
isolation of T cells and in vitro differentiation, isolation of memory cells and
recall assays, and isolation of T cells from lamina propria was performed as
described in the Supplemental Experimental Procedures.
RNA-Seq
Whole-transcriptome amplification of cell lysates was performed by SMART-
seq (Ramsko¨ld et al., 2012) using the Fluidigm C1 Single-Cell Auto Prep Sys-
tem, followed by Nextera XT DNA Sample Preparation (Illumina), as described
in the Supplemental Experimental Procedures. We collected at least two inde-
pendent biological replicates for each in vivo and in vitro condition and two
technical replicates for two in vivo conditions.
RNA-Seq Preprocessing
RNA-seq reads alignment and transcript quantification were performed
as described in the Supplemental Experimental Procedures. We used logegulatory Genes across Single Cells
ne (row) its expression distribution across single cells differentiated under the
le: proportion of cells expressing in each of the 17 expression bins (columns).
he Spearman correlation coefficients between the single-cell expression levels
es (columns) and the single-cell expression of any other bimodally expressed
es are clustered.
sh key variation. Each cell (TGF-b1+IL-6, 48 hr) is colored by a signature score
cells are colored by an expression ranking score of a key gene, denoted on top.
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transform and quantile normalization to further normalize the expression
values (FPKM) within each batch of samples (i.e., all single cells in a given
run) and accounted for low (or zero) expression by adding a value of 1 prior
to log transform. For each library, we computed quality scores using Fastqc,
Picard tools, and in-house scripts, excluding poor libraries from further anal-
ysis and further adjusting for the quality scores (Supplemental Experimental
Procedures).
Batch Correction
We performed batch correction separately for in vivo and in vitro samples.
A filtered gene set consists of the genes that have an expression level
exceeding 10 FPKM in at least 20% of the cells of a given sample (Supple-
mental Experimental Procedures).
Taking into Account False Negatives Using a Weighted Analysis
To account for the effect of each gene’s expression and each cell’s quality
on the probability of false negatives with zero transcript abundance, we
construct for each cell a false-negative curve (FNC) representing the false-
negative rate as a function of transcript abundance in the bulk population
and use this to weight subsequent analyses (Supplemental Experimental
Procedures).
Signature Scores and Gene Set Enrichment Analysis
To interpret the functional implications of the variation between cells, we
assembled a set of gene signatures that are indicative of various cell states.
A typical signature is comprised of a ‘‘plus’’ subset and a ‘‘minus’’ subset.
A strong match will have extreme and opposite values for the expression of
genes in the two sets (Supplemental Experimental Procedures).
Gene Ranking
We rank genes in the co-variation modules that significantly correlate
(Spearman correlation with FDR < 0.05, using the Benjamini-Hochberg
scheme) with at least one of the genes in the curated set of bimodally
expressed immune response genes (columns of Figure 4B) by five criteria
(Supplemental Experimental Procedures): (1) correlation with the first PC in
the in-vitro-derived Th17 cells (using TGF-b1+IL6) (2) correlation with the first
and (3) second PCs in the in-vivo-derived Th17 cells; (4) correlation with im-
mune-related genes that are specified in the columns of Figure 4B; (5) a similar
analysis using a curated pathogenicity signature (genes that are positively or
negatively associated with pathogenic Th17 cells based on population-level
experiments [Lee et al., 2012]).ACCESSION NUMBERS
All RNA-seq data are submitted to GEO, with the accession number GEO:
GSE74833.Figure 5. Gpr65, Toso, and Plzp Are Validated as T Cell Pathogenicity
(A and B) Reduction in IL17A-producing cells in Gpr65/ T cells differentiated
GPR65/ cells differentiated for 96 hr. (B) Quantification of secreted IL-17A and
**p < 0.01, ***p < 0.001. Error bars represent SD; n = 3.
(C) Reduced IL-17A and IFN-g production by Gpr65/ memory (CD62LCD44+
(D) Loss of GPR65 reduces tissue inflammation and autoimmune disease in vivo.R
Gpr65/ CD4+ T cells and were induced with EAE 1 week post transfer. Error b
(E) Transcriptional impact of a loss of GPR65, TOSO, and PLZP. Shown is the sig
that are dysregulated compared to WT during the TGF-b1+IL-6 differentiation of
(F and G) Reduction in IL17A-producing cells in Toso/ T cells differentiated in vit
activated in vitro for 96 hr. (G) Quantification of secreted IL-17A and IL-17F for W
(H) Reduced IL-17A production by Toso/ LN memory T cells in a recall assay a
(I) Hampered IL-17A production by Plzp/ CD4+ T cells in an in vitro recall assa
IFN-g (y axis) and IL-17A (x axis).
(J) Quantification of secreted IL-17A and IL-17F of a MOG35-55 recall assay for litt
representative of at least three independent experiments with at least three expe
See also Figure S7 and Table S6.
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in vitro. (A) Intracellular cytokine staining for IFN-g and IL-17A of CD4+ WT or
Il-17F by cytometric bead assays (CBA) in corresponding samples. *p < 0.05,
CD4+) T cells in a recall assay (Supplemental Experimental Procedures).
AG-1/mice (n = 10 per category) were reconstitutedwith 23 106 naiveWT or
ars represent SD.
nificance of enrichment (log10 [p value]; hypergeometric test, y axis) of genes
Gpr65/ (96 hr), Plzp/ (48 hr) and Toso/ (96 hr) cells.
ro. (F) Intracellular cytokine staining as in (A) but for WT or Toso/CD4+ T cells
T or Toso/ CD4+ T cells, as in (B). Error bars represent SD; n = 3.
s in (C).
y (Supplemental Experimental Procedures). Intracellular cytokine staining for
ermate controls and PLZP/mice at 96 hr post ex vivo. All experiments are a
rimental replicates per group. Error bars represent SD; n = 3.
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